Prostaglandin E2 EP receptors in cardiovascular disease: An update.
Animals
Cardiovascular Diseases
/ metabolism
Dinoprostone
/ metabolism
Humans
Models, Cardiovascular
Receptors, Prostaglandin E, EP1 Subtype
/ metabolism
Receptors, Prostaglandin E, EP2 Subtype
/ metabolism
Receptors, Prostaglandin E, EP3 Subtype
/ metabolism
Receptors, Prostaglandin E, EP4 Subtype
/ metabolism
Regeneration
Arrhythmia
Blood pressure
Heart
Ischemia
Prostaglandin E2
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
23
09
2021
revised:
11
11
2021
accepted:
16
11
2021
pubmed:
26
11
2021
medline:
20
1
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
This review article provides an update for the role of prostaglandin E2 receptors (EP1, EP2, EP3 and EP4) in cardiovascular disease. Where possible we have reported citations from the last decade although this was not possible for all of the topics covered due to the paucity of publications. The authors have attempted to cover the subjects of ischemia-reperfusion injury, arrhythmias, hypertension, novel protein binding partners of the EP receptors and their pathophysiological significance, and cardiac regeneration. These latter two topics bring studies of the EP receptors into new and exciting areas of research that are just beginning to be explored. Where there is peer-reviewed literature, the authors have placed particular emphasis on clinical studies although these are limited in number.
Identifiants
pubmed: 34822808
pii: S0006-2952(21)00484-6
doi: 10.1016/j.bcp.2021.114858
pii:
doi:
Substances chimiques
Receptors, Prostaglandin E, EP1 Subtype
0
Receptors, Prostaglandin E, EP2 Subtype
0
Receptors, Prostaglandin E, EP3 Subtype
0
Receptors, Prostaglandin E, EP4 Subtype
0
Dinoprostone
K7Q1JQR04M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114858Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.